Evaluation of ability of OR51T1 expression to predict primary hormone therapy efficacy among men with hormone-naive metastatic prostate cancer.

被引：0
|
作者：
Mochizuki, Taku
Miyoshi, Yasuhide
Kawahara, Takashi
Yokomizo, Yumiko
Hayashi, Narihiko
Yao, Masahiro
Miyamoto, Hiroshi
Uemura, Hiroji
机构：
[1] Yokohama City Univ Med Ctr, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ Grad Sch Med, Yokohama, Kanagawa, Japan
[3] Johns Hopkins Sch Med, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.317
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
317
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
    Armstrong, K.
    Ahmad, I.
    Kalna, G.
    Tan, S. S.
    Edwards, J.
    Robson, C. N.
    Leung, H. Y.
    BRITISH JOURNAL OF CANCER, 2011, 105 (09) : 1362 - 1369
  • [22] Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
    K Armstrong
    I Ahmad
    G Kalna
    S S Tan
    J Edwards
    C N Robson
    H Y Leung
    British Journal of Cancer, 2011, 105 : 1362 - 1369
  • [23] Upfront docetaxel with androgen deprivation therapy in the elderly patient with metastatic hormone-naive prostate cancer: Single institution experience.
    Rayner, Lindsay Jennifer Andrew
    Challapalli, Amarnath
    Blackmore, Eve
    Rea, Katherine
    Wells, Natasha
    White, Paul
    Hilman, Serena
    Masson, Susan
    Huckett, Rebecca
    Garadi, Krishna
    Kirk, Hannah
    Kabala, Julian
    Oikonomopoulou, Viktoria
    Bahl, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [24] Does expression of TMPRSS2: ERG fusion gene in lymph node metastases predict response to endocrine therapy in hormone-naive prostate cancer?
    Boormans, J. L.
    Verhagen, P. C. M. S.
    Ziel-Van der Made, A. C. J.
    Leenders, Van G. J. L. H.
    Trapman, J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 254 - 254
  • [25] Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis
    Sun, Guijiang
    Chen, Xuanrong
    Gong, Xue
    Chen, Yawei
    Li, Guilai
    Wei, Fang
    Jiang, Aili
    Niu, Yuanjie
    Shang, Zhiqun
    FUTURE ONCOLOGY, 2019, 15 (10) : 1167 - 1179
  • [26] Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
    Calcagno, Fabien
    Mouillet, Guillaume
    Adotevi, Olivier
    Maurina, Tristan
    Nguyen, Thierry
    Montcuquet, Philippe
    Curtit, E.
    Kleinclauss, F.
    Pivot, Xavier
    Borg, Christophe
    Thiery-Vuillemin, Antoine
    MEDICAL ONCOLOGY, 2016, 33 (08)
  • [27] Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
    Fabien Calcagno
    Guillaume Mouillet
    Olivier Adotevi
    Tristan Maurina
    Thierry Nguyen
    Philippe Montcuquet
    E. Curtit
    F. Kleinclauss
    Xavier Pivot
    Christophe Borg
    Antoine Thiery-Vuillemin
    Medical Oncology, 2016, 33
  • [28] Efficacy of abiraterone acetate for high-risk hormone-naive metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
    Kanao, Kent
    Takahashi, Takayuki
    Umezawa, Yuta
    Okabe, Takashi
    Kaneko, Go
    Shirotake, Suguru
    Nishimoto, Koshiro
    Oyama, Masafumi
    PLOS ONE, 2022, 17 (10):
  • [29] What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
    Vale, C. L.
    Fisher, D. J.
    White, I. R.
    Carpenter, J. R.
    Burdett, S.
    Clarke, N. W.
    Fizazi, K.
    Gravis, G.
    James, N. D.
    Mason, M. D.
    Parmar, M. K. B.
    Rydzewska, L. H.
    Sweeney, C. J.
    Spears, M. R.
    Sydes, M. R.
    Tierney, J. F.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1249 - 1257
  • [30] The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naive Prostate Cancer Patients
    Sasaki, Takeshi
    Sugimura, Yoshiki
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (12)
12345